Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica.
about
Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa RicaMajor clinical research advances in gynecologic cancer in 2015Current global status & impact of human papillomavirus vaccination: Implications for IndiaLong-term efficacy and safety of human papillomavirus vaccinationEffect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine TrialDistribution patterns of infection with multiple types of human papillomaviruses and their association with risk factorsRationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa RicaCross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections.Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection.Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.Determinants of seropositivity among HPV-16/18 DNA positive young women.Correlates of cervicovaginal human papillomavirus detection in perimenopausal women.Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trialsImmunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.Prospects for prevention of HPV-driven oropharynx cancer.An updated natural history model of cervical cancer: derivation of model parameters.Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates.Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial.Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections.HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays.HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection.Logistic analysis of epidemiologic studies with augmentation sampling involving re-stratification and population expansionReduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial.Performance of self-collected cervical samples in screening for future precancer using human papillomavirus DNA testing.Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease.Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial.Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18-25 years enrolled in a clinical trialA prospective study of absolute risk and determinants of human papillomavirus incidence among young women in Costa Rica.Human papillomavirus types by age in cervical cancer precursors: predominance of human papillomavirus 16 in young women.Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirusEfficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial.Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposureProof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine.Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa RicaNeutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera.A review of clinical trials of human papillomavirus prophylactic vaccines.Prevalence of and risk factors for anal human papillomavirus infection among young healthy women in Costa Rica.Evaluation of the FTA carrier device for human papillomavirus testing in developing countries.HPV vaccine: One, two, or three doses for cervical cancer prevention?Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(®)
P2860
Q21089767-A513B3F1-6DF5-4842-A11B-93F6DF7DCEE7Q28077183-7FA08595-3CBB-460A-A60E-8ED69B89A425Q28079776-2AA6CBD0-311C-4C98-8378-B5BF77D0BEE6Q28081156-3DE21486-2C69-48B0-9C3E-4C1FB38AC0E6Q28607942-5CCA26FE-9868-4EC9-B2EF-B356AE635457Q28742649-E568D67A-5961-429A-9AFA-DAECC214915DQ30300329-F06767C6-5E8C-4945-AB9A-DE721CD65D83Q30353668-AFBA229C-32D3-4A5D-8FD4-D3C2ADDF2868Q30354637-2BFF2C54-59E1-4922-A095-2608245AE142Q30970916-2EA85432-BD81-4B9C-8B7D-A2A2B6041552Q30986936-923145BD-54DD-41AE-886B-BB924BF476A8Q33675027-C076DF8B-B277-4782-A41C-15FF00A4B00BQ33699365-EC714963-912E-492E-9906-87A350A21AD8Q33723312-08B73788-6CAE-495D-808B-302B66984D29Q33759930-1CDF87D1-FB20-40AC-BF8B-BFDC870AC1FBQ34083083-930347EC-CD98-4835-BEA1-0D7A5FB890F9Q34149348-9A6A126E-F84F-4851-A2F9-4E496F15DA05Q34199560-0C729E5A-04D7-4E28-A719-4AD601D598BFQ34267472-9FBEA547-5DCC-405B-A428-90F8D314E8A1Q34542304-9775444C-C89B-49F5-92D0-3D0EECAFD326Q34612818-7293ECF9-1299-4572-869A-4240F1C91F9FQ34678206-101DD70B-E093-4659-AB9B-1CCF91521280Q34736045-5145E0B9-2741-4F7B-AAD4-9B12F0779FE8Q34736619-3EC5F57A-BB63-412A-8133-4BA20AD3ABE7Q34743370-71A305F4-4C68-4AE7-91A1-EB537AA0F0ECQ34776171-F75A5A4A-7BCC-4300-AB69-C1B1A88EECB9Q34776205-BC010078-A90E-4D0A-94CA-524A312D3511Q34802732-ECDAC41B-321D-4737-A14F-EE11D1C5ACC5Q34959801-229E2627-03F6-425A-BFEF-D5E361C275EBQ35109451-A259993D-0219-40F8-B65A-DA08C99597CDQ35212868-AE7BEB44-78FA-487E-8D38-A8612BD49BDDQ35228757-FB02F73C-F345-40A7-9AAC-27ED10B35C15Q35268615-049F0A65-B234-47EE-A1B4-2C770D304802Q35967430-83545C49-5C2B-4C2B-830E-0754CE62E08BQ35985515-D6A363C2-08A3-4BB0-BB9A-384417E6D5C3Q36259403-27923F42-3322-4B73-A687-EE91AB778835Q36402155-635A8863-54B8-4AB1-A212-322CF2D85F84Q36414176-40014506-0B6A-4FDA-883A-B7F79CFCC5E2Q36457994-7A73890E-B91B-4042-BB21-AFA0619708D9Q36480943-DD708F8C-7DBB-4793-B1F1-BFCEAF801A86
P2860
Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Rationale and design of a comm ...... ine in Guanacaste, Costa Rica.
@en
Rationale and design of a comm ...... ine in Guanacaste, Costa Rica.
@nl
type
label
Rationale and design of a comm ...... ine in Guanacaste, Costa Rica.
@en
Rationale and design of a comm ...... ine in Guanacaste, Costa Rica.
@nl
prefLabel
Rationale and design of a comm ...... ine in Guanacaste, Costa Rica.
@en
Rationale and design of a comm ...... ine in Guanacaste, Costa Rica.
@nl
P2093
P2860
P50
P1433
P1476
Rationale and design of a comm ...... ine in Guanacaste, Costa Rica.
@en
P2093
Bernal Cortés
Carolina Porras
Concepción Bratti
Costa Rica Vaccine Trial (CVT) Group
Diane Solomon
Diego Guillen
Douglas Lowy
Enrique Freer
John Schiller
P2860
P304
P356
10.1016/J.VACCINE.2008.07.002
P407
P577
2008-07-18T00:00:00Z